Your Shopping Cart Is Empty
| Report Code: A10311 | Feb 2021 | Pages: 181 | ||
| Tables: 105 | Charts: 60 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the European Antibiotics Market
Request Now !The European Antibiotics Market size was valued at $11,561.2million in 2019, and is projected to reach $13,529.8million by 2027 at a CAGR of 1.9% from 2020 to 2027.
Antibiotics are medicines that fight bacterial infections in people and animals. They work by killing the bacteria or by making it hard for the bacteria to grow and multiply.In addition, they are used to cure several diseases such as strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, ear infections, and others. There are numerous ways of classifying antibiotics, however, the most common classification is based on their chemical structures, spectrum of activity, and mode of action. Currently, the demand for beta lactam and beta lactamase inhibitors class of antibiotics is high among healthcare providers.
Almost every nation is dealing with the outbreak. Most markets are dropping down as COVID-19 outbreak has negatively affected various healthcare-related markets. This pandemic is expected to present growth opportunities for European antibiotics in the future.It is imperative to be aware of the unreported amounts of antibiotics that have been administered globally in just a few months and a marked increase in antimicrobial resistance should therefore be expected.Information on antimicrobial treatments given to patients with SARS-CoV-2 infection is rare. Although the antimicrobials used have been reported in some studies, there is insufficient consideration of their importance or of the possibility that they are being used broadly or inappropriately, especially when broad-spectrum antibiotics are used in combination. For instance, according to Journal of Antimicrobial Chemotherapy, 15% of COVID-19 patients received antifungal treatment and 71% received antibiotic treatment, 25% of whom were treated with a single antibiotic and 45% with combination therapy. The antibiotics used were cephalosporins, quinolones, carbapenems, tigecycline (against MRSA), and linezolid. Many sick patients received antibacterial therapy, such as moxifloxacin (64%), ceftriaxone (25%) and azithromycin (18%). The administration of antibiotics was also reported in a case of a neonate with non-specific symptoms of COVID-19 infection; this neonate received fluid therapy, oxygen therapy, and antibiotic therapy with vancomycin and amikacin.
There is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The European antibiotics market is segmented on the basis of class, drug origin, spectrum of activity, route of administration, and country. By class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, Carbapenem, and Monobactam. By drug origin, the market is categorized into natural, semisynthetic, and synthetic. By spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By route of administration, the market is divided into oral, intravenous, and others.
By Drug class, beta lactam & beta lactamase inhibitors segment was the major revenue contributor in 2019, and is anticipated to continue this trend during the forecast period due to its spectrum of activity. These antibiotics are a class of broad-spectrum antibiotics. A broad-spectrum antibiotic acts against both Gram-positive & Gram-negative bacteria and effective on the infections with multiple groups of bacteria. Thus, the demand for beta lactam & beta lactamase inhibitors antibiotics is high. On the other side, the demand for quinolones is projected to exhibit the fastest European antibioticsmarket growth during the forecast period owing to the rise in demand of broad-spectrum bactericidal activity new generation quinolones, excellent oral bioavailability, good tissue penetration, and better safety & tolerability.
By drug origin, semisynthetic function presently dominates the European antibioticsmarket, and is expected to remain dominant during the forecast period. This is attributed to the fact that the semisynthetic antibiotics have improved coverage and effectiveness against a wide range of organisms. Also, the semisynthetic antibiotics can be administered either parenterally or orally as well as less costly to administer than other antibiotics in some cases. The synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and a low probability for developing resistance.
The key players operating in the European antibiotics market include Abbott Laboratories, Abbvie Inc. (Allergan Plc.), Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Viatris Inc., Novartis International AG (Sandoz), Pfizer Inc., and Sanofi.
Key Benefits For Stakeholders
European Antibiotics Market Report Highlights
| Aspects | Details |
|---|---|
| By DRUG CLASS |
|
| By Drug Origin |
|
| By Spectrum Of Activity |
|
| By Route Of Administration |
|
| By Country |
|
| Key Market Players | PFIZER INC., ABBOTT LABORATORIES, F. HOFFMANN-LA ROCHE LTD., BAYER AG., VIATRIS INC.(MYLAN), ABBVIE INC.(ALLERGEN), SANOFI, MERCK & CO. INC., GLAXOSMITHKLINE PLC, NOVARTIS INTERNATIONAL AG (SANDOZ) |
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2019
3.4. Porter’s five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of infectious diseases
3.5.1.2. Development of novel approaches for new antibiotics for treating bacterial infections
3.5.2. Restraints
3.5.2.1. Development of antibiotic resistance
3.5.2.2. The time taken for the regulatory approval
3.5.3. Opportunities
3.5.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.
3.5.4. Impact analysis
3.6. Impact of COVID-19 on European Antibiotic Market
CHAPTER 4: EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market analysis, by country
4.2.3. Market size and forecast, by type
4.2.3.1. Penicillin
4.2.3.1.1. Market size and forecast
4.2.3.2. Cephalosporin
4.2.3.2.1. Market size and forecast
4.2.3.3. Carbapenem
4.2.3.3.1. Market size and forecast
4.2.3.4. Monobactam
4.2.3.4.1. Market size and forecast
4.3. Quinolone
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market analysis, by country
4.4. Macrolide
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market analysis, by country
4.5. Other
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market analysis, by country
CHAPTER 5: EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN
5.1. Overview
5.1.1. Market size and forecast
5.2. Natural
5.2.1. Market analysis, by country
5.3. Semisynthetic
5.3.1. Market analysis, by country
5.4. Synthetic
5.4.1. Market analysis, by country
CHAPTER 6: EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY
6.1. Overview
6.1.1. Market size and forecast
6.2. Broad spectrum antibiotics
6.2.1. Market analysis, by country
6.3. Narrow spectrum antibiotics
6.3.1. Market analysis, by country
CHAPTER 7: EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Market analysis, by country
7.3. Intravenous
7.3.1. Market analysis, by country
7.4. Others
7.4.1. Market analysis, by country
CHAPTER 8: EUROPEAN ANTIBIOTIC MARKET, BY COUNTRY
8.1. Europe
8.1.1. Key market trends, growth factors, and opportunities
8.1.2. Market size and forecast, by country
8.1.2.1. Germany
8.1.2.1.1. Germany antibiotic Market, by drug class
8.1.2.1.2. Germany antibiotic market, by drug origin
8.1.2.1.3. Germany antibiotic market, by spectrum of activity
8.1.2.1.4. Germany antibiotic market, by route of administration
8.1.2.2. France
8.1.2.2.1. France antibiotic market, by drug class
8.1.2.2.2. France antibiotic market, by drug origin
8.1.2.2.3. France antibiotic market, by spectrum of activity
8.1.2.2.4. France antibiotic market, by route of administration
8.1.2.3. UK
8.1.2.3.1. UK antibiotic market, by drug class
8.1.2.3.2. UK antibiotic market, by drug origin
8.1.2.3.3. UK antibiotic market, by spectrum of activity
8.1.2.3.4. UK antibiotic market, by route of administration
8.1.2.4. Italy
8.1.2.4.1. Italy antibiotic market, by drug class
8.1.2.4.2. Italy antibiotic market, by drug origin
8.1.2.4.3. Italy antibiotic market, by spectrum of activity
8.1.2.4.4. Italy antibiotic market, by route of administration
8.1.2.5. Spain
8.1.2.5.1. Spain Antibiotic market, by drug class
8.1.2.5.2. Spain antibiotic market, by drug origin
8.1.2.5.3. Spain antibiotic market, by spectrum of activity
8.1.2.5.4. Spain antibiotic market, by route of administration
8.1.2.6. Rest of Europe
8.1.2.6.1. Rest of Europe antibiotic market, by drug class
8.1.2.6.2. Rest of Europe antibiotic market, by drug origin
8.1.2.6.3. Rest of Europe antibiotic market, by spectrum of activity
8.1.2.6.4. Rest of Europe antibiotic market, by route of administration
8.1.3. Europe antibiotics market, by drug class
8.1.4. Europe antibiotics market, by drug origin
8.1.5. Europe antibiotics market, by spectrum of activity
8.1.6. Europe antibiotics market, by route of administration
CHAPTER 9: COMPANY PROFILES
9.1. ABBOTT LABORATORIES
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. ABBVIE INC.(ALLERGEN)
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. BAYER AG.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.4. F. HOFFMANN-LA ROCHE LTD.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. GLAXOSMITHKLINE PLC
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. MERCK & CO. INC.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. VIATRIS INC.(MYLAN)
9.7.1. Company overview
9.7.2. Operating business segments
9.7.3. Product portfolio
9.7.4. Key strategic moves and developments
9.8. NOVARTIS INTERNATIONAL AG (SANDOZ)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. PFIZER INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.10. SANOFI
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027 ($MILLION)
TABLE 02. BETA LACTAM & BETA LACTAMASE INHIBITORS, BY TYPE, 2019–2027 ($MILLION)
TABLE 03. EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027 ($MILLION)
TABLE 04. EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027 ($MILLION)
TABLE 05. EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 06. EUROPEAN ANTIBIOTIC MARKET REVENUE, BY COUNTRY, 2019–2027($MILLION)
TABLE 07. GERMANY STERILE GLOVES MARKET, BY DRUG CLASS , 2019–2027
TABLE 08. GERMANY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 09. GERMANY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 10. GERMANY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 11. FRANCE ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027
TABLE 12. FRANCE ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 13. FRANCE ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 14. FRANCE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 15. UK ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027
TABLE 16. UK ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 17. UK ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 18. UK ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 19. ITALY ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027
TABLE 20. ITALY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 21. ITALY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 22. ITALY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 23. SPAIN ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027
TABLE 24. SPAIN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 25. SPAIN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 26. SPAIN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 27. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027
TABLE 28. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)
TABLE 29. REST OF EUROPE EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)
TABLE 30. REST OF EUROPE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)
TABLE 31. EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS , 2017-2025 ($MILLION)
TABLE 32. EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 33. EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 34. EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 35. ABBOTT: COMPANY SNAPSHOT
TABLE 36. ABBOTT: OPERATING SEGMENTS
TABLE 37. ABBOTT: PRODUCT PORTFOLIO
TABLE 38. ABBVIE: COMPANY SNAPSHOT
TABLE 39. ABBVIE: OPERATING SEGMENT
TABLE 40. ABBVIE: PRODUCT PORTFOLIO
TABLE 41. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 42. BAYER: COMPANY SNAPSHOT
TABLE 43. BAYER: OPERATING SEGMENTS
TABLE 44. BAYER: PRODUCT PORTFOLIO
TABLE 45. ROCHE: COMPANY SNAPSHOT
TABLE 46. ROCHE: OPERATING SEGMENTS
TABLE 47. ROCHE: PRODUCT PORTFOLIO
TABLE 48. GSK: COMPANY SNAPSHOT
TABLE 49. GSK: OPERATING SEGMENTS
TABLE 50. GSK: PRODUCT PORTFOLIO
TABLE 51. MERCK: COMPANY SNAPSHOT
TABLE 52. MERCK: OPERATING SEGMENTS
TABLE 53. MERCK: PRODUCT PORTFOLIO
TABLE 54. VIATRIS: COMPANY SNAPSHOT
TABLE 55. VIATRIS: OPERATING SEGMENTS
TABLE 56. VIATRIS: PRODUCT PORTFOLIO
TABLE 57. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 58. NOVARTIS: OPERATING SEGMENTS
TABLE 59. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 60. PFIZER: COMPANY SNAPSHOT
TABLE 61. PFIZER: OPERATING SEGMENTS
TABLE 62. PFIZER: PRODUCT PORTFOLIO
TABLE 63. SANOFI: COMPANY SNAPSHOT
TABLE 64. SANOFI: OPERATING SEGMENTS
TABLE 65. SANOFI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. EUROPEAN ANTIBIOTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE EUROPEAN ANTIBIOTICS MARKET
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2021*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2021*
FIGURE 06. TOP PLAYER POSITIONING, 2019
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09. LOW THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. EUROPEAN ANTIBIOTIC MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 14. PENICILLIN ANTIBIOTICS MARKET, 2019–2027 ($MILLION)
FIGURE 15. CEPHALOSPORIN ANTIBIOTICS MARKET, 2019–2027 ($MILLION)
FIGURE 16. CARBAPENEM ANTIBIOTICS MARKET, 2019–2027 ($MILLION)
FIGURE 17. MONOBACTAM ANTIBIOTICS MARKET, 2019–2027 ($MILLION)
FIGURE 18. EUROPEAN ANTIBIOTIC MARKET FOR QUINOLONES, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 19. EUROPEAN ANTIBIOTIC MARKET FOR MACROLIDE, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 20. EUROPEAN ANTIBIOTIC MARKET FOR OTHER, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 21. EUROPEAN NATURAL ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 22. EUROPEAN SEMISYNTHETIC ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 23. EUROPEAN SYNTHETIC INHIBITORS ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 24. EUROPEAN ANTIBIOTIC MARKET FOR BROAD SPECTRUM ANTIBIOTICS, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 25. EUROPEAN ANTIBIOTIC MARKET FOR NARROW SPECTRUM ANTIBIOTICS, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 26. EUROPEAN ORAL ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 27. EUROPEAN INTRAVENOUS ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 28. EUROPEAN ANTIBIOTIC MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
FIGURE 29. GERMANY ANTIBIOTIC MARKET, 2019-2027 ($MILLION)
FIGURE 30. FRANCE ANTIBIOTIC MARKET, 2019-2027 ($MILLION)
FIGURE 31. UK ANTIBIOTIC MARKET, 2019-2027 ($MILLION)
FIGURE 32. ITALY ANTIBIOTIC MARKET FOR ITALY, 2019-2027 ($MILLION)
FIGURE 33. SPAIN ANTIBIOTIC MARKET, 2019-2027 ($MILLION)
FIGURE 34. REST OF EUROPE ANTIBIOTIC MARKET, 2019-2027 ($MILLION)
FIGURE 35. ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 36. ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 37. ABBOTT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38. ABBVIE: NET SALES, 2017–2019 ($MILLION)
FIGURE 39. ABBVIE: REVENUE SHARE BY REGION, 2019(%)
FIGURE 40. BAYER: NET SALES, 2017–2019 ($MILLION)
FIGURE 41. BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42. BAYER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43. ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 44. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 46. GSK: NET SALES, 2017-2019 ($MILLION)
FIGURE 47. GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 48. GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 49. MERCK: NET SALES, 2017-2019 ($MILLION)
FIGURE 50. MERCK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 51. MERCK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 52. NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 53. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 54. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 55. PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 56. PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 57. PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 58. SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 59. SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 60. SANOFI: REVENUE SHARE BY REGION, 2019 (%)
In accordance with several interviews conducted,growth of European antibiotics market is expected to increase due to substantial investments in R&D activities by several biotech companies and favorable government legislations.
As per the CXOs, rise in prevalence of infectious diseases, and development of novel approaches for new antibiotics for treating bacterial infections & a large number of clinical trials are projected to drive the market growth during the forecast period. However, development of antibiotic resistance, driven by misuse of antibiotics and the increase in drug approval costs are expected to hinder the market growth.
The CXOs further added that, Spain has the highest share of the market in 2019, attributable to the presence of no legislation on obtaining antibiotics without prescription as well as low prices of antibiotics. For instance, at the time of the launch of antibiotics, France was consuming more antibiotics than any other country in Europe. In addition, doctors are freely given out antibiotics which increases the antimicrobial resistance in the region. Therefore, the consumption of antibiotics and antimicrobial resistance gives opportunity to manufacturer for new inventions.
A. The total market value of European Antibiotic Market is $11,561.27 million in 2019.
A. The forcast period for European Antibiotic Market is 2020 to 2027
A. The market value of European Antibiotic Market in 2027 is $13,529.83 million.
A. The base year is 2019 in European Antibiotic Market
A. Top companies such as,Abbott Laboratories, Abbvie Inc. (Allergan Plc.), Bayer, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Viatris Inc., Novartis International AG (Sandoz), Pfizer Inc., and Sanofi held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in rigions.
A. Beta lactam & beta lactamase inhibitors segment was the major revenue contributor in 2019, and is anticipated to continue this trend during the forecast period due to its spectrum of activity.
A. The major factor that fuels the growth of the European Antibiotic Market includes rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth.
A. Antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections.
A. Antibiotics are used to treat or prevent some types of bacterial infections. They are not effective against viral infections, such as the common cold or flu.
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report